NCAM1 and hepatocellular carcinoma: Description: The present invention refers to a method for the production of activated CD3-CD56+ NK cells; activated CD3-CD56 NK+ cells obtainable with the method; and their use, in particular for the treatment of a tumor (preferably a hepatocellular carcinoma (HCC)), for use in the treatment and/or prevention of an HCV infection, for use in the treatment and/or prevention of a post-liver transplant HCV reinfection, or for use for the prevention of a post-liver transplant HCC recurrence.